Rifaximin (Xifaxan) News, Updated Regularly

Salix Receives FDA Complete Response Letter for Balsalazide Tablet - Carolina Newswire
December 29, 2008, 10:22 pm

RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for balsalazide tablet studied as ...

Mild-to-moderate Active Ulcerative Colitis - Salix Receives FDA ... - Medical News Today
January 2, 2009, 3:58 pm

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for balsalazide tablet studied as a treatment of ...

Are you looking for additional Xifaxan (Rifaximin) news? Try our new "Rifaximin News Focus" area.

Are you looking for additional Xifaxan (Rifaximin) information? Try our new "Rifaximin Related Blog Entries" area.

Off-site Rifaximin (Xifaxan) Links, User Submitted

The following links have been collected through user bookmark submission in the Rifaximin_Xifaxan category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Tue May 22

• Antibiotic Treatment of Crohn's Disease

Sat Apr 14

• The Effects of Rifaximin on the Symptoms of IBS: Pimentel_Annal s of Internal Medicine_Octob er 17, 2006

Fri Nov 10

• Rifaximin for Irritable Bowel Syndrome

Mon Jul 10

• RIFAXIMIN

Off-site Rifaximin Research Links

If you still need additional information on Rifaximin then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.